Imatinib
Cancer Brain
University of UtahSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
36 Active assets in the Cancer Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan University of California, Davis | Phase 2 | BBB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Cyclophosphamide Essen Biotech | Phase 2 | BB |
Sorafenib Virginia Commonwealth University | Phase 2 | BB |
DIANHYDROGALACTITOL Kintara Therapeutics, Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →